478 related articles for article (PubMed ID: 12857560)
61. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia.
Zetterquist H; Mattsson J; Uzunel M; Näsman-Björk I; Svenberg P; Tammik L; Bayat G; Winiarski J; Ringdén O
Bone Marrow Transplant; 2000 Apr; 25(8):843-51. PubMed ID: 10808205
[TBL] [Abstract][Full Text] [Related]
62. Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation.
Dahlke J; Kröger N; Zabelina T; Ayuk F; Fehse N; Wolschke C; Waschke O; Schieder H; Renges H; Krüger W; Kruell A; Hinke A; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2006 Jan; 37(2):155-63. PubMed ID: 16284608
[TBL] [Abstract][Full Text] [Related]
63. Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cells?
Schilham MW; Balduzzi A; Bader P;
Bone Marrow Transplant; 2005 Mar; 35 Suppl 1():S49-52. PubMed ID: 15812531
[TBL] [Abstract][Full Text] [Related]
64. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial.
Ribera JM; Oriol A; Bethencourt C; Parody R; Hernández-Rivas JM; Moreno MJ; del Potro E; Torm M; Rivas C; Besalduch J; Sanz MA; Ortega JJ;
Haematologica; 2005 Oct; 90(10):1346-56. PubMed ID: 16219571
[TBL] [Abstract][Full Text] [Related]
65. Engraftment and chimerism, particularly of T- and B-cells, in children undergoing allogeneic bone marrow transplantation.
Winiarski J; Mattsson J; Gustafsson A; Wester D; Borgström B; Ringdén O; Ljungman P; Dalianis T
Pediatr Transplant; 1998 May; 2(2):150-6. PubMed ID: 10082448
[TBL] [Abstract][Full Text] [Related]
66. Analysis of donor-type chimerism in lineage-specific cell populations after allogeneic myeloablative and non-myeloablative stem cell transplantation.
Miura Y; Tanaka J; Toubai T; Tsutsumi Y; Kato N; Hirate D; Kaji M; Sugita J; Shigematsu A; Iwao N; Ota S; Masauzi N; Fukuhara T; Kasai M; Asaka M; Imamura M
Bone Marrow Transplant; 2006 May; 37(9):837-43. PubMed ID: 16547484
[TBL] [Abstract][Full Text] [Related]
67. Allogeneic hematopoietic SCT in patients with non-malignant diseases, and importance of chimerism.
Svenberg P; Mattsson J; Ringdén O; Uzunel M
Bone Marrow Transplant; 2009 Dec; 44(11):757-63. PubMed ID: 19421178
[TBL] [Abstract][Full Text] [Related]
68. A low body mass index is correlated with poor survival after allogeneic stem cell transplantation.
Le Blanc K; Ringdén O; Remberger M
Haematologica; 2003 Sep; 88(9):1044-52. PubMed ID: 12969813
[TBL] [Abstract][Full Text] [Related]
69. [Allogeneic hematopoietic stem cell transplantation for acute lymphocytic leukemia].
Chen H; Ren HY; Guo NL; Huang XJ; Liu KY; Xu LP; Zhang YC; Zheng H; Wu T; Liu DH; Yang SM; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2004 Feb; 25(2):87-90. PubMed ID: 14990046
[TBL] [Abstract][Full Text] [Related]
70. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
[TBL] [Abstract][Full Text] [Related]
71. Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation.
Bacher U; Badbaran A; Fehse B; Zabelina T; Zander AR; Kröger N
Exp Hematol; 2009 Jan; 37(1):135-42. PubMed ID: 19100523
[TBL] [Abstract][Full Text] [Related]
72. Quantitative chimerism kinetics in relapsed leukemia patients after allogeneic hematopoietic stem cell transplantation.
Qin XY; Li GX; Qin YZ; Wang Y; Wang FR; Liu DH; Xu LP; Chen H; Han W; Wang JZ; Zhang XH; Li JL; Li LD; Liu KY; Huang XJ
Chin Med J (Engl); 2012 Jun; 125(11):1952-9. PubMed ID: 22884060
[TBL] [Abstract][Full Text] [Related]
73. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission.
Kiehl MG; Kraut L; Schwerdtfeger R; Hertenstein B; Remberger M; Kroeger N; Stelljes M; Bornhaeuser M; Martin H; Scheid C; Ganser A; Zander AR; Kienast J; Ehninger G; Hoelzer D; Diehl V; Fauser AA; Ringden O
J Clin Oncol; 2004 Jul; 22(14):2816-25. PubMed ID: 15254049
[TBL] [Abstract][Full Text] [Related]
74. Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up.
Oyekunle AA; Kröger N; Zabelina T; Ayuk F; Schieder H; Renges H; Fehse N; Waschke O; Fehse B; Kabisch H; Zander AR
Bone Marrow Transplant; 2006 Jan; 37(1):45-50. PubMed ID: 16258531
[TBL] [Abstract][Full Text] [Related]
75. Molecular monitoring of T-cell chimerism early after allogeneic stem cell transplantation may predict the occurrence of acute GVHD grades II-IV.
Jaksch M; Uzunel M; Remberger M; Sundberg B; Mattsson J
Clin Transplant; 2005 Jun; 19(3):346-9. PubMed ID: 15877796
[TBL] [Abstract][Full Text] [Related]
76. Prognostic factors for relapsed childhood acute lymphoblastic leukemia: impact of allogeneic stem cell transplantation--a report from the Kyushu-Yamaguchi Children's Cancer Study Group.
Matsuzaki A; Nagatoshi Y; Inada H; Nakayama H; Yanai F; Ayukawa H; Kawakami K; Moritake H; Suminoe A; Okamura J
Pediatr Blood Cancer; 2005 Aug; 45(2):111-20. PubMed ID: 15782402
[TBL] [Abstract][Full Text] [Related]
77. [Effects of allogeneic hematopoietic stem cell transplantation with very-high-dose conditioning regimen for refractory leukemia].
Liu QF; Sun J; Xu D; Zhang Y; Fan ZP; Wei YQ; Meng FY; Zhou SY
Di Yi Jun Yi Da Xue Xue Bao; 2004 Oct; 24(10):1117-9. PubMed ID: 15485779
[TBL] [Abstract][Full Text] [Related]
78. Detailed monitoring of hematopoietic chimerism in a child treated by adoptive immunotherapy for high risk of relapse after BMT for acute myeloid leukemia.
Formánková R; Honzátková L; Sieglová Z; Starý J; Sedlácek P; Brdicka R
Bone Marrow Transplant; 2000 Feb; 25(4):453-6. PubMed ID: 10723591
[TBL] [Abstract][Full Text] [Related]
79. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.
Grigg AP; Gibson J; Bardy PG; Reynolds J; Shuttleworth P; Koelmeyer RL; Szer J; Roberts AW; To LB; Kennedy G; Bradstock KF
Biol Blood Marrow Transplant; 2007 May; 13(5):560-7. PubMed ID: 17448915
[TBL] [Abstract][Full Text] [Related]
80. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]